Omixon
Business Services · Hungary · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Fehérvári Ave 50-52, Budapest, Budapest,...Phone Number
+36 705748001Website
www.omixon.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Omixon
Omixon is a molecular diagnostics company that focuses on empowering clinical labs with Next Generation Sequencing (NGS) technologies to improve patient outcomes, particularly in the HLA typing sector. The company offers innovative products like the Holotype HLA, NanoTYPE, and HoloGRAFT ONE designed for HLA genotyping and related research applications. Targeted towards histocompatibility labs and researchers, Omixon's solutions enable the integration of advanced NGS methodologies into clinical workflow. Recently acquired by Werfen, Omixon continues to lead the adoption of NGS technology to enhance transplant outcomes globally.Explore more
Omixon Org Chart
EM
Field Applications Scientist
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Omixon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Omixon has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Omixon
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Omixon, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Omixon launches new products
Click to see if Omixon had a recent Job posting/layoffs
Check out if Omixon is spiking on competitors!
Funding: Get notified immidiatlly once Omixon has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Omixon recently announced quarterly report
Recommended Actions
Find VP level buyers at Omixon
Find 2 more new buyers
Company Profile Activity
Activity Insights
Omixon is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Omixon is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Omixon.
Omixon Tech Stack
A closer look at the technologies used by Omixon
See more technologies
Omixon News & Media
Omixon acquires Organ Monitoring Group BV
Omixon to commercialize a cell-free DNA assay for transplant monitoring developed and validated by a transplant physician BUDAPEST, HUNGARY, June 4, 2022 /EINPresswire.com/ -- Omixon Biocomputing, Kft announced today that it has completed a …Omixon and SeqOnce Biosciences Announce an Extension to the AzureSeq-200 CE One-step RT-qPCR Assay to Detect SARS-CoV-2 N501Y Variant
Assay quickly identifies the N501Y mutation found in U.K., South Africa and Brazil lineages of SARS-CoV-2 BUDAPEST, Hungary and PASADENA, Calif., Jan. 28, 2021 /PRNewswire/ -- Omixon and SeqOnce Biosciences, Inc., announce today the launch of a new extension to the AzureSeq One-Step...Omixon launches AzureSeq-200 CE kit for one-step RT-PCR detection of SARS-CoV-2 and announces exclusive agreement with SeqOnce Biosciences
Omixon announce the launch of Omixon AzureSeq-200 CE IVD kit for the detection of novel coronavirus SARS-CoV-2 by RT-PCR. The AzureSeq-200 CE technology uses a revolutionary workflow that detects viral RNA without RNA-extraction. (PRWeb October 07, 2020) Read the full story at https://www.prweb.com/releases/omixon_launches_azureseq_200_ce_kit_for_one_step_rt_pcr_detection_of_sars_cov_2_and_announces_exclusive_agreement_with_seqonce_biosciences/prweb17445941.htmOmixon launches OmniType, multiplex for NGS-based HLA genotyping
OmniType offers a revolutionary single working-day workflow that allows processing of samples from gDNA to a ready-to-sequence library in about 6 hours and achieving final results that can be reported early the next day. (PRWeb September 30, 2020) Read the full story at https://www.prweb.com/releases/omixon_launches_omnitype_multiplex_for_ngs_based_hla_genotyping/prweb17427909.htm
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Omixon
Sign Up For FreeTo access detailed company insights
Omixon is a molecular diagnostics company that focuses on empowering clinical labs with Next Generation Sequencing (NGS) technologies to improve patient outcomes, particularly in the HLA typing sector. The company offers innovative products like the Holotype HLA, NanoTYPE, and HoloGRAFT ONE designed for HLA genotyping and related research applicati... Read More
